Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Publikation

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.

Wissenschaftlicher Artikel/Review - 07.12.2021

Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas

Zitation

Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Cancer Res Clin Oncol 2021; 148

Veröffentlichungsdatum

07.12.2021

eISSN (Online)

1432-1335

Seiten

647-656

Kurzbeschreibung/Zielsetzung

Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients.